United States Point of Care Diagnostics Market Overview, 2031

Key Insights

• According to the research report, "USA Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the USA Point of Care Diagnostics Market was valued at more than 14.35 Billion in 2025.
• The primary operational transformation in the U.S. Point of Care (POC) testing landscape is the migration of high-complexity lab assays to CLIA-waived, decentralized platforms. Advanced microfluidic lab-on-a-chip technologies and multiplex PCR systems allow non-laboratory clinical personnel to execute rapid viral, bacterial, and biomarker assays at the bedside. A major clinical breakthrough in this segment includes FDA clearances for rapid, high-sensitivity point-of-care diagnostics, such as point-of-care traumatic brain injury (TBI) blood biomarkers, point-of-care STI assays, and rapid Bordetella detection platforms delivering lab-grade quantitative diagnostic accuracy in under 15 minutes.
• Point-of-care testing in the U.S. has evolved beyond simple qualitative test strips into fully connected diagnostic nodes. Modern POC platforms incorporate biosensors paired with cloud connectivity and AI-driven predictive algorithms. This automation automatically validates quality control metrics, flags abnormal biomarker patterns, and wirelessly pushes diagnostic records directly into a hospital’s EHR system minimizing pre-analytical and post-analytical transcription errors. Over 515 million bedside blood glucose test strips are consumed annually across U.S. hospital settings alone, driven by tight glycemic control protocols for the estimated 34+ million Americans diagnosed with diabetes.
• Next-generation biosensor technologies are closing the sensitivity gap that historically limited point-of-care test performance compared to centralized core laboratories. Combining microfluidic design with advanced electrochemical biosensors yields sensitivity improvements of approximately 22.5% over traditional lateral flow test strips. These performance gains are expanding POC usage into acute care environments like emergency departments and intensive care units, where rapid, highly sensitive diagnostic decisions are critical.

Market Outlook

• The market outlook is defined by a shift toward institutional cost-reduction strategies and value-based care frameworks across U.S. healthcare systems. Hospital networks are increasingly leveraging point-of-care testing to reduce patient emergency department length-of-stay, optimize triage pathways, and lower readmission risks for chronic metabolic and cardiovascular conditions. Concurrently, consumer and outpatient testing patterns are driving rapid adoption of over-the-counter (OTC) and pharmacy-administered POC diagnostics, creating a dual-track market divided between high-volume hospital acute care systems and decentralized home/community care models.
• Major companies shaping the U.S. point-of-care landscape include Abbott Laboratories, F. Hoffmann-La Roche, Danaher Corporation, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, and Nova Biomedical, alongside critical oversight and guidance from key regulatory and clinical bodies such as the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and the American Association for Clinical Chemistry (AACC / Association for Diagnostics & Laboratory Medicine).

Market Dynamics

Driver: Rising demand for rapid and decentralized healthcare
There is an increasing shift toward decentralized healthcare settings (such as urgent care clinics, retail pharmacies, and home-based care). Patients and providers heavily favor point-of-care (POC) diagnostics because they deliver immediate results, enabling faster clinical decision-making, shorter hospital stays, and improved disease management particularly for infectious diseases and chronic conditions.
Challenge: Stringent and lengthy regulatory approval processes
Bringing a new POC diagnostic device to the US market requires navigating rigorous evaluation pathways by the FDA (Center for Devices and Radiological Health). The complex requirements for clinical trials, analytical validation, and obtaining a CLIA waiver can cause substantial time-to-market delays and high development costs for manufacturers.
Trend: Integration of digital health and connectivity
Modern POC devices are increasingly integrated with Bluetooth, Wi-Fi, and cloud-based data management systems. This connectivity allows test results from decentralized locations (or home kits) to sync instantly into electronic health records (EHRs), streamlining multi-site compliance tracking, remote patient monitoring, and public health data reporting.

Policies

• FDA Device Clearance/Approval (Pre-Market Review): Manufacturers must secure 510(k) clearance, Premarket Approval (PMA), or De Novo classification from the FDA to legally market a diagnostic device, ensuring safety and efficacy.
• Clinical Laboratory Improvement Amendments (CLIA) Categorization: The FDA and the Centers for Medicare & Medicaid Services (CMS) classify tests based on complexity (Waived, Moderate, or High Complexity). Securing a CLIA Waiver is vital for POC devices intended for non-traditional settings (like pharmacies or physician offices) to minimize regulatory burdens.
• CMS Certification and Inspection: Facilities operating POC diagnostics must hold the appropriate type of CLIA Certificate (e.g., Certificate of Waiver or Certificate of Compliance) issued by CMS or a CMS-approved accreditation body (like the College of American Pathologists or The Joint Commission).
• Quality System Regulations / Quality Management System (QMSR/ISO 13485): Manufacturers must maintain robust quality management systems for design, manufacturing, and distribution, aligning with FDA quality system requirements.
• Post-Market Surveillance and Medical Device Reporting (MDR): Under 21 CFR Part 803 and Part 806, manufacturers are legally obligated to monitor fielded devices, report malfunctions or adverse events to the FDA, and manage field corrections or recalls across distributed testing sites.

Segment Analysis

USA Point of Care Diagnostics By Product
• Glucose monitoring kits are evolving from standalone finger-stick meters into connected diabetes-management ecosystems that can incorporate digital applications, Bluetooth connectivity, cloud-based reporting, and integration with broader remote-care workflows. The distinctive feature of this segment is its recurring relationship with patients: unlike many one-time diagnostic tests, glucose monitoring can generate a continuous stream of measurements that supports medication management, lifestyle decisions, and clinician follow-up.
• Infectious-disease POC testing is shifting from simple antigen detection toward broader multiplex and molecular workflows capable of distinguishing between pathogens with overlapping symptoms. A particularly distinctive U.S. characteristic is the coexistence of rapid retail/home tests with increasingly capable professional systems used in emergency, urgent-care, physician-office, and other decentralized settings. Recent FDA CLIA-waiver decisions illustrate this movement, including waived systems for respiratory-virus combinations, group A strep, sexually transmitted infections, and other molecular or antigen-based applications.
• Pregnancy and fertility testing occupies an unusual position within POC diagnostics because consumer autonomy and privacy are central to product design. The segment extends beyond conventional pregnancy-result tests into ovulation prediction and fertility-oriented testing, creating demand for products that are easy to interpret and suitable for repeated use. Digital readers and smartphone-connected formats can add interpretation and cycle-tracking functionality, turning an individual test into part of a broader reproductive-health workflow.
• POC hematology is differentiated by the challenge of bringing measurements traditionally associated with laboratory analyzers closer to the patient without creating an excessively complicated workflow. The segment includes applications such as blood-cell measurements and coagulation-related testing, where rapid information can influence immediate clinical decisions. Compact analyzers, cartridge-based systems, automated sample handling, and simplified operator procedures are particularly important because they allow testing to move into emergency, urgent-care, physician-office, and other settings where conventional laboratory infrastructure may not be immediately available.
• Cardiometabolic POC products increasingly combine several aspects of risk assessment rather than functioning as isolated diagnostic devices. Depending on the product, the category can encompass lipid-related measurements, cardiovascular biomarkers, blood-pressure monitoring, and other metabolic indicators, creating opportunities for integrated screening and chronic-disease management. A distinctive U.S. trend is the movement of cardiometabolic testing across multiple care environments: hospitals can use rapid measurements to support acute decisions, while outpatient and home settings can use them for longitudinal monitoring.
• Urinalysis is particularly well suited to decentralized diagnostics because urine can be collected noninvasively and analyzed using relatively compact formats. Dipsticks remain important because they can simultaneously screen multiple biochemical characteristics, while more advanced POC systems can automate strip reading and reduce subjective interpretation. In the U.S., this creates a bridge between basic screening and more sophisticated automated analysis in physician offices, urgent-care environments, and other decentralized facilities.
• Cholesterol test strips represent a consumer-oriented branch of cardiometabolic POC testing where simplicity and accessibility are major differentiators. Their appeal comes from enabling lipid-related measurements without requiring a conventional laboratory visit, making them relevant to screening and self-monitoring environments. Product development increasingly focuses on minimizing sample handling, simplifying result interpretation, and connecting measurements with broader digital health experiences.
• The other-products category captures a broad innovation layer that does not fit neatly into the major established POC segments, including specialized biomarker tests, multi-analyte systems, toxicology-related testing, fecal-occult testing, and emerging application-specific platforms. Its distinctive characteristic is fragmentation: products can address relatively narrow clinical problems but still benefit from the same decentralization trend driving the wider POC industry.

USA Point of Care Diagnostics By Technology/Platform
• Lateral flow assays remain a foundational POC technology because they translate complex biochemical recognition into a visually or instrumentally readable format with relatively simple sample handling. Their major differentiator is operational simplicity: many formats require limited equipment and can be adapted for professional, retail, and home settings. The platform is particularly important for infectious-disease, pregnancy, and other rapid screening applications, while newer instrument-assisted readers can improve interpretation and potentially extend lateral-flow formats beyond purely visual tests.
• Molecular POC diagnostics bring nucleic-acid amplification closer to the patient, reducing the traditional separation between centralized molecular laboratories and rapid clinical decision-making. PCR and isothermal nucleic-acid amplification technologies can provide substantially more analytical specificity than many conventional rapid antigen approaches, while cartridge-based systems simplify sample preparation, amplification, and result interpretation.
• Microfluidics and immunoassays are important because they enable multiple biochemical processes to be compressed into small cartridges or automated instruments. Microfluidic architectures can control very small sample volumes and integrate functions such as mixing, separation, reaction, and detection, while immunoassay chemistry enables targeted detection of proteins, hormones, antibodies, antigens, and other biomarkers. In the U.S., the combination is particularly attractive for platforms seeking laboratory-like functionality with a smaller footprint and simplified operation.
• Dipsticks and test strips represent one of the most accessible forms of POC testing because they generally require little instrumentation and can produce results directly at the testing site. Their strength is not technological complexity but practicality: low equipment requirements, straightforward workflows, portability, and compatibility with urine, blood, and other specimen types make them useful across professional and self-testing environments.

USA Point of Care Diagnostics By End-User
• Hospitals and critical-care environments use POC diagnostics primarily where the clinical value of a result depends on obtaining it during the patient's immediate care episode. Emergency departments, intensive-care units, operating rooms, and other acute settings can use decentralized testing to shorten the distance between specimen collection and clinical action.
• Clinical and diagnostic laboratories occupy a hybrid position in the POC ecosystem: they remain associated with centralized, high-capacity testing while increasingly supporting decentralized instruments, satellite facilities, physician-office laboratories, and near-patient testing programs. Their distinctive role is often quality oversight, method verification, connectivity, training, and interpretation rather than simply performing every test themselves. As POC platforms become more sophisticated, laboratories can help ensure that decentralized results remain compatible with broader laboratory-quality systems.
• Home care and self-testing are transforming POC diagnostics from a healthcare-facility activity into an increasingly consumer-facing service. The defining characteristic is that the user may collect the specimen, operate the test, interpret the result, and decide whether to seek professional care without a laboratory professional physically present. This makes intuitive instructions, error-resistant design, clear result interpretation, connectivity, privacy, and regulatory clearance especially important.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Point of Care Diagnostics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Glucose Monitoring Kits
• Infectious Diseases Testing Kits
• Pregnancy And Fertility Testing Kits
• Hematology Testing Kits
• Cardiometabolic Monitoring Kits
• Urinalysis Testing Kits
• Cholesterol Test Strips
• Other Products

By Technology/Platform
• Lateral Flow Assays
• Molecular Diagnostics (PCR/INAAT)
• Microfluidics & Immunoassays
• Dipsticks & Test Strips

By End-User
• Hospitals & Critical Care Centers
• Clinical & Diagnostic Laboratories
• Home Care & Self-Testing

By Mode Of Purchase
• Prescription Based Products
• OTC Products

By Sample
• Blood
• Urine
• Nasal and Oropharyngeal Swabs